IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 1.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 7,265,253 shares of the company’s stock after acquiring an additional 78,797 shares during the quarter. Janus Henderson Group PLC owned about 0.08% of IDEAYA Biosciences worth $242,023,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd increased its stake in IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of IDEAYA Biosciences by 5.2% in the 4th quarter. Russell Investments Group Ltd. now owns 9,683 shares of the company’s stock valued at $335,000 after buying an additional 476 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after buying an additional 580 shares during the last quarter. Finally, Comerica Bank raised its stake in IDEAYA Biosciences by 36.5% during the 4th quarter. Comerica Bank now owns 2,514 shares of the company’s stock worth $87,000 after acquiring an additional 672 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Wells Fargo & Company raised their price objective on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Truist Financial decreased their target price on IDEAYA Biosciences from $65.00 to $63.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Citigroup reaffirmed a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Friday, May 22nd. Finally, Wall Street Zen upgraded shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

IDEAYA Biosciences Stock Up 2.4%

Shares of IDYA stock opened at $36.45 on Friday. The stock’s 50-day moving average price is $33.56 and its 200 day moving average price is $32.66. The stock has a market capitalization of $3.20 billion, a PE ratio of -22.78 and a beta of -0.09. IDEAYA Biosciences, Inc. has a 52-week low of $22.09 and a 52-week high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period last year, the firm earned ($0.82) earnings per share. The company’s revenue for the quarter was down 39.4% compared to the same quarter last year. Analysts expect that IDEAYA Biosciences, Inc. will post -4.1 earnings per share for the current fiscal year.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares of the company’s stock, valued at $1,058,904.66. This trade represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.70% of the stock is currently owned by corporate insiders.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.